Upstream Bio, Inc. (UPB)
NASDAQ: UPB · Real-Time Price · USD
14.69
-13.12 (-47.18%)
At close: Feb 11, 2026, 4:00 PM EST
14.98
+0.29 (1.97%)
After-hours: Feb 11, 2026, 7:59 PM EST
Upstream Bio Revenue
Upstream Bio had revenue of $683.00K in the quarter ending September 30, 2025, with 12.52% growth. This brings the company's revenue in the last twelve months to $2.80M, up 26.82% year-over-year. In the year 2024, Upstream Bio had annual revenue of $2.37M, down -0.42%.
Revenue (ttm)
$2.80M
Revenue Growth
+26.82%
P/S Ratio
271.63
Revenue / Employee
$53,827
Employees
52
Market Cap
793.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.37M | -10.00K | -0.42% |
| Dec 31, 2023 | 2.38M | 1.17M | 96.37% |
| Dec 31, 2022 | 1.21M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionUPB News
- 16 hours ago - Upstream Bio Shows Asthma Drug Cuts Attacks By 56%, Stock Reacts - Benzinga
- 19 hours ago - Upstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma - GlobeNewsWire
- 1 day ago - Upstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe Asthma - GlobeNewsWire
- 5 weeks ago - Upstream Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study - Seeking Alpha
- 2 months ago - Upstream Bio to Participate in Upcoming December Investor Conferences - GlobeNewsWire
- 3 months ago - Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress - GlobeNewsWire
- 3 months ago - Upstream Bio to Participate in Upcoming November Investor Conferences - GlobeNewsWire